Monday, October 13, 2014 9:29:48 AM
Analysts at Barclays initiated coverage on shares of Foamix Pharmaceuticals (NASDAQ: FOMX) with a Overweight rating.
The target price for Foamix Pharmaceuticals is set to $11.
Foamix Pharmaceuticals' shares fell 3.61% to close at $5.08 on Friday
Pharmaceuticals (NASDAQ:FOMX) | Benzinga
http://www.benzinga.com/analyst-ratings/initiation/14/10/4916444/barclays-initiates-foamix-pharmaceuticals-at-overweight
It may not be much money, but it's mine dammit to hell, not 'yours'.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM